FDA Approves Once-Daily Vizz for Presbyopia

FDA approves once-daily Vizz for presbyopia

The FDA approved Vizz for the treatment of presbyopia in adults, according to a press release from Lenz Therapeutics.Once-daily Vizz (aceclidine ophthalmic solution 1.44%) contracts the iris sphincter muscle, creating a pinhole effect to extend depth of focus and improve near vision without a myopic shift, according to the release.

FDA Approves Aceclidine-Based Eye Drop Vizz for Presbyopia Treatment

The U.S. Food and Drug Administration (FDA) has approve […]

Vizz Becomes First, Only FDA-Approved Aceclidine-Based Eye Drop for Presbyopia

The FDA approves aceclidine ophthalmic solution 1.44%, the first aceclidine eye drop for presbyopia, offering a new solution for millions struggling with near vision loss.

Lenz Therapeutics Receives FDA Approval of VIZZ for the Treatment of Presbyopia

A new, first-of-its kind presbyopia drop will soon be available in the US as the FDA approved Lenz Therapeutics' VIZZ (aceclidine ophthalmic solution) 1.44%. VIZZ, which is expected to be broadly available in the fourth quarter of 2025, is the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults. “The FDA approval of VIZZ is a defining moment for Lenz and represents a transformative improvement in the a…

FDA approves Lenz Therapeutics’ VIZZ for the treatment of presbyopia

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution to correct vision for up to 10 hours.

FDA approved Lenz Therapeutics’ VIZZ for the treatment of presbyopia

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution to correct vision for up to 10 hours.